| Drug Name |
Baricitinib |
| Drug ID |
BADD_D02487 |
| Description |
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signalling molecules and proinflammatory mediators.
Rheumatoid arthritis is a progressive autoimmune disease commonly associated with discomfort, diasability, and joint damage. Throughout disease progression, the disease may further lead to joint erosions and deformities, causing premature mortality, functional impairment, and reduced quality of life [A31386]. While there are several disease modifying antirheumatic drugs (DMARDs) available for treatment, patients often experience inadequate threapeutic resposes to these drugs. In animal models of inflammatory arthritis, baricitinib was shown to have significant anti-inflammatory effects, but also led to preservation of cartilage and bone, with no detectable suppression of humoral immunity or adverse hematologic effects [A31382].
In the EU, baricitinib was approved in February of 2017 as a second-line orally administered treatment for moderate to severe active rheumatoid arthritis in adults, either as a monotherapy or when combined with methotrexate. It is marketed under the trade name Olumiant.
Baricitinib in combination with [remdesivir] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on 19 November 2020.[L22619] |
| Indications and Usage |
Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate. |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA37 |
| DrugBank ID |
DB11817
|
| KEGG ID |
D10308
|
| MeSH ID |
C000596027
|
| PubChem ID |
44205240
|
| TTD Drug ID |
D0Y7IC
|
| NDC Product Code |
0002-4182; 0110-4182; 14501-0104; 52076-6225; 0002-4479; 0002-6885; 0110-4732; 63419-0552; 59651-639; 0002-4732; 0110-4479 |
| UNII |
ISP4442I3Y
|
| Synonyms |
baricitinib | 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)- | INCB-28050 | Olumiant | baricitinib phosphate | baricitinib phosphate salt | 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-, phosphate (1:1) | INCB028050 | INCB-028050 | LY3009104 | LY-3009104 |
